A number of large multi-centre studies are now open for recruitment or are just about to open. More sites are needed for recruitment and anyone interested should contact the Chief Investigator or their CLRN Lead who is listed at http://www.bsg.org.uk/research/general/using-the-comprehensive-clinical-research-network.html. Read on and join in...

Barrett’s Oesophagus Surveillance Study

The aim of the study is to see whether endoscopic surveillance is better than no endoscopic surveillance for the prevention of early mortality in patients diagnosed with Barrett’s oesophagus. The study randomises patients to receive a standard upper gastrointestinal endoscopy with biopsy every two years for 10 years or endoscopy at the time of need (no protocol endoscopic surveillance). All patients will receive a bi-annual postal questionnaire to record their symptoms and other health related data (administered by the centre. Patients will be recruited over 2 years and followed up for a further 10 years. The chief investigator is Prof Hugh Barr ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ).

A multicentre trial of infliximab and ciclosporin in steroid-resistant active severe colitis. There was an initial pilot phase which has gone well. Six centres have full approval and will start recruitment in March. The recruitment target is 480 patients, and the plan is to do this from at least 40 sites across the UK. If you would like more information please email This e-mail address is being protected from spambots. You need JavaScript enabled to view it , or contact the trial coordinator, Anne Seagrove, directly on 01792 513411, email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

A multicentre RCT of the efficacy of 6-MP in the prevention of recurrence of Crohn’s Disease after ileo-colonic or small bowel resection. Patients are recruited within 3 months of surgery. Patients will receive 6MP or placebo for up to 3 years (156 weeks) and attend 12 study visits during this time.

STOPAH (steroids or pentoxifylline in Alcoholic Hepatitis) is a multicentre UK trial funded by NIHR. This is a vital study in UK hepatology looking to prove the role of steroids or pentoxyfilline versus placebo in the treatment of a condition which is increasingly common in the UK. Patients with DF>32 are eligible and the study is designed to be pragmatic with few exclusions to treatment. Primary outcome is 30-day mortality but with follow-up to a year.
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it